Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients

Hilde A. M. Kooistra; Martin Gebel; Kurtulus Sahin; Anthonie W. A. Lensing; Karina Meijer

doi:10.1160/TH14-12-1033

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2015; 114(06): 1136-1143
DOI: 10.1160/TH14-12-1033

Coagulation and Fibrinolysis

Schattauer GmbH

Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients

Data from the EINSTEIN-DVT and PE studies

Hilde A. M. Kooistra

¹Division of Haemostasis and Thrombosis, Department of Haematology, University of Groningen, University Medical Centre Groningen, The Netherlands

,

Martin Gebel

²Bayer HealthCare, Wuppertal, Germany

,

Kurtulus Sahin

³ClinStat GmbH, Cologne, Germany

,

Anthonie W. A. Lensing

²Bayer HealthCare, Wuppertal, Germany

,

Karina Meijer

¹Division of Haemostasis and Thrombosis, Department of Haematology, University of Groningen, University Medical Centre Groningen, The Netherlands

› Institutsangaben

Abstract

Summary

Vitamin K antagonists (VKA) are used to prevent recurrent disease in patients with venous thromboembolism (VTE). Their efficacy and safety depend on individual time in therapeutic range (iTTR) and variability of International Normalised Ratios (INR). We aimed to identify independent predictors of poor VKA control > 28 days. In a prospective cohort of 3825 VTE patients, separate logistic regression analyses were performed to identify predictors of low iTTR (first quartile) and instability (iTTR <median and variability >median). Subsequently, the association between these predictors and clinical outcomes was investigated. Weight < 50 kg (odds ratio [OR]=1.89; 95 % confidence interval [CI] 1.03–3.49), active cancer at baseline (OR=1.52; CI1.05–2.19), secondary VTE (OR=1.42; CI1.20–1.68), and INR < 2.0 at stop of double therapy (OR=1.35; CI1.09–1.67) were independent predictors of low iTTR. The first two were also predictive for instability (OR=1.96; CI1.06–3.63 and OR=1.95; CI1.36–2.80, respectively). ORs of early ( 28 days) low iTTR and instability depended on VKA type. In acenocoumarol users, early low iTTR was an independent predictor of subsequent low iTTR (OR=1.92; CI1.31–2.80) and instability (OR=1.55; CI1.07–2.23). In warfarin users, early low iTTR (OR=1.36; CI1.09–1.69) and instability (OR=1.25; CI1.01–1.55) were additionally predictive for low iTTR, but only the latter was predictive for instability (OR=1.91; CI1.57–2.32). Many predictors of VKA control also predicted premature discontinuation, but only region was prognostic for clinical outcome. In conclusion, we identified several independent predictors of low iTTR and instability > 28 days, which showed some similarities but did not fully overlap. Early VKA control was of additional value for prediction of both, but had to be interpreted in the context of VKA type.

Keywords

Venous thrombosis - vitamin K antagonists - predictors - iTTR - instability

Volltext

Referenzen

References
1 Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2006; 01: CD001367.
2 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
3 White HD, Gruber M, Feyzi J. et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167: 239-245.
4 Veeger NJ, Piersma-Wichers M, Tijssen JG. et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005; 128: 513-519.
5 Rose AJ, Hylek EM, Ozonoff A. et al. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes 2011; 04: 22-29.
6 Lind M, Fahlen M, Kosiborod M. et al. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res 2012; 129: 32-35.
7 Razouki Z, Ozonoff A, Zhao S. et al. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range. Circ Cardiovasc Qual Outcomes 2014; 07: 664-669.
8 van Leeuwen Y, Rosendaal FR, Cannegieter SC. Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. J Thromb Haemost 2008; 06: 451-456.
9 Apostolakis S, Sullivan RM, Olshansky B. et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013; 144: 1555-1563.
10 Rose AJ, Hylek EM, Ozonoff A. et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 08: 2182-2191.
11 Ibrahim S, Jespersen J, Poller L. et al. The clinical evaluation of International Normalized Ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate. J Thromb Haemost 2013; 11: 1540-1546.
12 EINSTEIN Investigators. Bauersachs R, Berkowitz SD. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
13 EINSTEIN-PE Investigators. Buller HR, Prins MH. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
14 Prins MH, Lensing AW, Bauersachs R. et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21-9560–11–21.
15 Rosendaal FR, Cannegieter SC, van der Meer FJ. et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
16 Limdi NA, Beasley TM, Baird MF. et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20: 912-921.
17 Rose AJ, Sharman JP, Ozonoff A. et al. Effectiveness of warfarin among patients with cancer. J Gen Intern Med 2007; 22: 997-1002.
18 Poli D, Antonucci E, Testa S. et al. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014; 09: 443-447.
19 Witt DM, Delate T, Clark NP. et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009; 114: 952-956.
20 Witt DM, Delate T, Clark NP. et al. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost 2010; 08: 744-749.
21 Gallego P, Roldan V, Marin F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
22 Wan Y, Heneghan C, Perera R. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 01: 84-91.
23 Beyer-Westendorf J, Ageno W. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost 2014; 113: 231-246.